Psoriasis Therapeutics Market Growth PowerPoint PPT Presentations

The report on Psoriasis Therapeutics Market by molecule (biologics, small molecules), route of administration (oral, parenteral, topical), dosage forms (solid, liquid, EMI-solid ), mechanism of action (TNF inhibitors, PDE4 inhibitors, il blocker) trends analysis and forecasts up to 2023 studies the market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-Pacific, Rest of the World. According to the report the Global Psoriasis Therapeutics Market is projected to grow at a CAGR of 9.7% in terms of value over the period of 2017-2023. The growth in the world market is primarily driven by significant contribution by North America (Leading region) region to this market.

GBI Research, the leading business intelligence provider, has released its latest research, Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. Detailed Report at: http://www.reportsandintelligence.com/psoriasis-therapeutics-in-asia-pacific-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-market

This report provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by the Research’s team of industry experts. 

This report provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by a team of industry experts. 

Psoriasis is a common immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes buildup of thick white, red, or silvery patches of skin. It alters the normal cell cycle of the skin. The new cells of the skin grow and move quickly to the surface of the skin to form patches known as "plaques". The plaques are commonly found on knees, elbows, scalp, hands, and feet. Psoriasis occurs mostly in adults, but can also be seen in children and adolescents. The etiology of the disease is unknown, however, it is believed to be an immune-mediated process. Read more details at: http://www.bigmarketresearch.com/global-psoriasis-therapeutics-2015-2019-market

The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research team of industry experts. Enquiry @ http://www.researchbeam.com/psoriasis-therapeutics-in-asia-pacific-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-market/enquire-about-report

Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. Read more details at: http://www.bigmarketresearch.com/psoriasis-therapeutics-in-asia-pacific-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-market

Download Sample Brochure@ http://tinyurl.com/gnovyco Marketintelreports, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects.

Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis and urticaria is expected to drive market growth during the forecast period.

The Psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination.

The Psoriasis market report thoroughly examines the market size, latest trends, and growth forecast. The report includes an overview of the disease and market scenario, as well as market trends, growth prospects, investment opportunities, and industry prospects. Additionally, it provides competitor analysis, regional analysis, and recent advancements in the Psoriasis market.

The Asia-Pacific Pruritus Therapeutics Market was valued at $2.0 billion in 2022 and is projected to reach $3.2 billion by 2032, registering a CAGR of 4.7% from 2023 to 2032.

According to the latest research report by IMARC Group, The global cytokine market size reached US$ 89.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 163.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.76% during 2024-2032. More Info:- https://www.imarcgroup.com/cytokine-market

Psoriasis Drug Market, [By Therapeutic Class (Interleukin Inhibitors, Tumour Necrosis Factor Inhibitors, Vitamin D-Analogues, Others); By Treatment Type (Topicals, Systematics, Biologics)]; and Geography - Trend, Analysis and Forecast

The Business Research Company offers biosimilar interleukins market research report 2023 with industry size, share, segments and market growth

The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics.

According to the latest research report by IMARC Group, The global CBD skin care market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.4 Billion by 2032, exhibiting a growth rate (CAGR) of 18.33% during 2024-2032. More Info:- https://www.imarcgroup.com/cbd-skin-care-market

The Global Autoimmune Disease Therapeutics Market size is expected to reach $149.4 billion by 2025, rising at a market growth of 4.34% CAGR during the forecast period. The autoimmune disease therapeutics market is anticipated to experience significant market growth during the forecast period due to early diagnosis of the disease, the latest launch of advanced therapy, and increased incidence of autoimmune disease. The market is witnessing a strong presence of late-stage pipeline drugs such as tocilizumab, baricitinib, olokizumab, apremilast, abatacept, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and others. On the other hand, higher costs associated with sophisticated therapy are anticipated to hamper the market growth. Full Report: https://www.kbvresearch.com/autoimmune-disease-therapeutics-market/

The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market. Read Complete Report @ http://www.researchbeam.com/anti-inflammatory-therapeutics-market On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Enquire @ http://www.researchbeam.com/anti-inflammatory-therapeutics-market/enquire-about-report

Anti-Inflammatory Therapeutics Market

The global seborrheic dermatitis market is expected to register a steady revenue CAGR during the forecast period. Seborrheic dermatitis is a common dermatological disorder both domestically and abroad. Seborrheic dermatitis is more prone to occur in immunocompromised patients, such as HIV patients, Lymphoma patients, and organ transplant recipients. A minor variation of seborrheic dermatitis is dandruff. Dandruff is much more common than seborrheic dermatitis, affecting about half of all adults across the globe.

The global biobanking market size is expected to reach USD 67.90 Billion in 2030 and register a revenue CAGR of 8.6% over the forecast period, according to latest analysis by Emergen Research.

TBRC global oral biologics and biosimilars market report includes lymphocyte modulators, interleukin inhibitors, and tumor necrosis factor-alpha inhibitors

TBRC published a new research report on “Biosimilar Interleukins Market Insights, to 2025" with new evolving trends, drivers, restraints, opportunities. https://bit.ly/39VWLVh

According to the latest research report by IMARC Group, The global autoimmune disease diagnosis market size reached US$ 3.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2027, exhibiting a growth rate (CAGR) of 6.4% during 2022-2027. More Info:- https://www.imarcgroup.com/autoimmune-disease-diagnosis-market

Infinium Global Research has added a new report on Global Psoriasis Therapeutics Market. The report predicts the market size of Psoriasis Therapeutics is expected to reach XX billion by 2023.

The report on Psoriasis Therapeutics by Infinium Global Research analyses the Psoriasis Therapeutics Market over the period of 2017 to 2023. This report also provides detailed qualitative and quantitative analyses of the market dynamics, market size and future trends in Global Psoriasis Therapeutics Market. It will help a lot of decision makers to develop strategies and find new opportunities in the Global Psoriasis Therapeutics Market.

The autoimmune disease treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 7.60% in the above-mentioned forecast period. Increasing awareness regarding healthcare sector drives the autoimmune disease treatment market. https://www.databridgemarketresearch.com/reports/global-autoimmune-disease-treatment-market

Looking forward, the autoimmune disease diagnosis market value is projected to reach a strong growth during the forecast period (2021-2026). More info:- https://www.imarcgroup.com/autoimmune-disease-diagnosis-market

Global dermatological therapeutics market would witness a CAGR of 7.90% and predicted to generate a revenue of $48.94 million by 2028.Read more

A recent report published by The Business Research Company on Biosimilar Interleukins Market provides in-depth analysis of segments and sub-segments in the global as well as regional. https://bit.ly/3nk0W25

Download Sample Brochure @ http://tinyurl.com/hrk5w6o Marketintelreports, ‘Psoriasis - Pipeline Review, H2 2015’, provides an overview of the Psoriasis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects.

Autoimmune diseases develop when body’s immune system recognizes the healthy body cells as foreign cells, and when immune system produces auto-antibodies that attack and destroy healthy tissues in the body rather than infectious agents. The disease is the hyperactive immune response against the substances and tissues normally present in the body and these are generally caused by genetic, infectious or environmental factors. It may lead to abnormal organ growth and changes in the functions of the organs.

The major players covered in the global oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S.... @ @ https://bit.ly/3gz5Nve

Psoriasis is a complex, chronic, multifactorial, inflammatory disease that involves hyperproliferation of the keratinocytes in the epidermis, with an increase in the epidermal cell turnover rate.

Get a sample brochure @ http://tinyurl.com/zmc69dn The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market.

The global sleep apnea devices market is expected to grow at a CAGR of 16.6% during the forecast period of 2014 to 2019. North America is the largest market in the global sleep apnea devices market, with a market share of 51.8% as of 2013, followed by Europe and Asia. The global sleep apnea devices market is broadly classified on the basis of segments, namely sleep apnea therapeutic devices and sleep apnea diagnostic devices. See Full Report: http://bit.ly/1JaPNW6

Big Market Research : World Anti-Inflammatory Therapeutics Market - Size, Share, Trends, Demand, Report, Opportunities and Forecast 2020 To Get More Details @ http://www.bigmarketresearch.com/anti-inflammatory-therapeutic-market Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells and heal injured tissues. Sometimes, the body defense system inappropriately triggers inflammation against its own cells, resulting in incurable inflammatory autoimmune diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD). According to World Health Organization (WHO), approximately 235 million people suffer from asthma in the world.

We believe there is an ample room for an efficacious affordable therapy to tap the mild to moderate RA pts population where biologics have not made a dent and expect few potential launches in 2014-15 (OTEZLA – apremilast, Xeljanz – tofacitinib) and onwards. In this report, we highlight the novel targets – oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis, compare their clinical trials data, and their commercial potential!

The Pruritus market report thoroughly examines the market size, latest trends, and growth forecast. The report includes an overview of the disease and market scenario, as well as market trends, growth prospects, investment opportunities, and industry prospects. Additionally, it provides competitor analysis, regional analysis, and recent advancements in the Pruritus market.

Autoimmune Diseases Market

Straits Research has just produced a new research study on the Psoriasis Drug market, which helps to influence the future of organisations by making well-informed business choices.

Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. See Full Report @ bit.ly/12yBegp

The global dermatology diagnostic devices market size reached US$ 16.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 34.4 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032.

The global jojoba oil derivatives market size reached US$ 192.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 355.1 Million by 2032, exhibiting a growth rate (CAGR) of 6.8% during 2024-2032.

The global topical drug delivery market is expected to register high revenue growth and reach a market size of USD 145.68 Billion by 2027, according to a current analysis by Emergen Research. The importance of topical drug formulations for pharmaceutical delivery is rapidly increasing, and rising demand and use of these types of products is contributing to increasing market size currently, and the trend for more convenient treatments at home is contributing to increasing market size.

The global autoinjector market is primarily driven by the increasing incidences of chronic and lifestyle diseases and the escalating demand for enhanced patient convenience. Additionally, individuals are rapidly shifting from conventional devices toward self-administrating devices, such as autoinjectors, due to the growing awareness regarding their benefits For an Executive Summary of Autoinjector Report Visit the following link: https://www.imarcgroup.com/autoinjector-market E-mail: sales@imarcgroup.com Contact: +91-120-415-5099

Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical..... @ @ https://bit.ly/3qztA1o

According to a new market report published by Persistence Market Research “Global Market Study on Biopharmaceuticals: Asia to Witness Highest Growth by 2020”, the global biopharmaceuticals market was valued at US$ 162 Bn in 2014 and is expected to grow at a CAGR of 9.4% from 2014 to 2020, to reach an estimated value of US$ 278 Bn by 2020.

According to a new market report published by Persistence Market Research “Global Market Study on Biopharmaceuticals: Asia to Witness Highest Growth by 2020”, the global biopharmaceuticals market was valued at US$ 162 Bn in 2014 and is expected to grow at a CAGR of 9.4% from 2014 to 2020, to reach an estimated value of US$ 278 Bn by 2020.

Read here the latest updates on the Vitiligo Drugs Market Analysis published by CMI team

According to the National Institutes of Health (NIH), around 23.5 million Americans are suffering from autoimmune disease.

In the realm of skincare, the landscape is constantly evolving, driven by advancements in science, technology, and consumer preferences. One significant niche within this expansive domain is the medicated skincare market. This sector encompasses a wide array of products formulated with active pharmaceutical ingredients (APIs) designed to address various skin concerns, from acne and eczema to aging and hyperpigmentation. As consumers increasingly seek solutions that combine efficacy with safety and convenience, the demand for medicated skincare continues to surge. This paper explores the dynamics of the medicated skincare market, delving into key trends, innovations, and future prospects shaping its trajectory. The global medicated skincare market expanded at 5.7% CAGR from 2012 to 2022 and reached a size of US$ 36.7 billion in 2022. The market is predicted to grow at a CAGR of 8% to reach a valuation of US$ 84.2 billion by the end of 2033.

Ustekinumab Market

Based on the recent publishing from the database of TheBusinessResearchCompany " Oral Biologics & Biosimilars Market Report" includes Emerging Trends, Drivers and Restraints. https://bit.ly/2VtunSn

Global inflammatory disease drug delivery market is set to witness a substantial CAGR of 7.8% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Increasing cases of inflammatory diseases among population is the major factor for the growth of this market.